CN105506160B - 幽门螺杆菌定量和毒力多重基因检测体系及其试剂盒和应用 - Google Patents
幽门螺杆菌定量和毒力多重基因检测体系及其试剂盒和应用 Download PDFInfo
- Publication number
- CN105506160B CN105506160B CN201610070257.3A CN201610070257A CN105506160B CN 105506160 B CN105506160 B CN 105506160B CN 201610070257 A CN201610070257 A CN 201610070257A CN 105506160 B CN105506160 B CN 105506160B
- Authority
- CN
- China
- Prior art keywords
- gene
- seq
- primer
- vaca
- nucleotide sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 181
- 238000001514 detection method Methods 0.000 title claims abstract description 58
- 241000590002 Helicobacter pylori Species 0.000 title claims abstract description 51
- 229940037467 helicobacter pylori Drugs 0.000 title claims abstract description 50
- 230000001018 virulence Effects 0.000 title claims abstract description 30
- 238000006243 chemical reaction Methods 0.000 claims abstract description 24
- 101150114014 cagA gene Proteins 0.000 claims abstract description 15
- 108020004465 16S ribosomal RNA Proteins 0.000 claims abstract description 11
- 238000003745 diagnosis Methods 0.000 claims abstract description 8
- 238000004445 quantitative analysis Methods 0.000 claims abstract description 6
- 239000002773 nucleotide Substances 0.000 claims description 66
- 125000003729 nucleotide group Chemical group 0.000 claims description 66
- 239000000203 mixture Substances 0.000 claims description 18
- 101150014144 ureC gene Proteins 0.000 claims description 12
- 101150078797 luxS gene Proteins 0.000 claims description 11
- 101150073660 glmM gene Proteins 0.000 claims description 10
- 239000013641 positive control Substances 0.000 claims description 10
- 239000013642 negative control Substances 0.000 claims description 9
- 239000003550 marker Substances 0.000 claims description 7
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 4
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 101710163270 Nuclease Proteins 0.000 claims description 3
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 3
- 239000013612 plasmid Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 108050009160 DNA polymerase 1 Proteins 0.000 claims 1
- 108060003196 globin Proteins 0.000 claims 1
- 102000018146 globin Human genes 0.000 claims 1
- 229910021642 ultra pure water Inorganic materials 0.000 claims 1
- 239000012498 ultrapure water Substances 0.000 claims 1
- 238000004458 analytical method Methods 0.000 abstract description 22
- 238000012360 testing method Methods 0.000 abstract description 16
- 206010019375 Helicobacter infections Diseases 0.000 abstract description 9
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 230000004907 flux Effects 0.000 abstract description 5
- 238000004393 prognosis Methods 0.000 abstract description 2
- 206010059866 Drug resistance Diseases 0.000 description 30
- 239000000523 sample Substances 0.000 description 24
- 238000005251 capillar electrophoresis Methods 0.000 description 19
- 239000012634 fragment Substances 0.000 description 17
- 238000000034 method Methods 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 11
- 229960002626 clarithromycin Drugs 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- 229960003022 amoxicillin Drugs 0.000 description 9
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 9
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 9
- 229960000282 metronidazole Drugs 0.000 description 9
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 6
- 101150039180 rdxA gene Proteins 0.000 description 6
- 230000007923 virulence factor Effects 0.000 description 6
- 239000000304 virulence factor Substances 0.000 description 6
- 229960001699 ofloxacin Drugs 0.000 description 5
- 241000589989 Helicobacter Species 0.000 description 4
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 4
- 230000001524 infective effect Effects 0.000 description 4
- 229960003376 levofloxacin Drugs 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000003321 amplification Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000711 cancerogenic effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 230000007918 pathogenicity Effects 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 210000001187 pylorus Anatomy 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 208000004300 Atrophic Gastritis Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000036495 Gastritis atrophic Diseases 0.000 description 1
- 101100439292 Helicobacter pylori cagA gene Proteins 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 101100346764 Mus musculus Mtln gene Proteins 0.000 description 1
- 101100476480 Mus musculus S100a8 gene Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- UOBPHQJGWSVXFS-UHFFFAOYSA-N [O].[F] Chemical compound [O].[F] UOBPHQJGWSVXFS-UHFFFAOYSA-N 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001262 anti-secretory effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 208000029162 bladder disease Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012502 diagnostic product Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 208000017215 gastric mucosa-associated lymphoid tissue lymphoma Diseases 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000011309 routine diagnosis Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 208000026533 urinary bladder disease Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 101150080234 vacA gene Proteins 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6851—Quantitative amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610070257.3A CN105506160B (zh) | 2016-02-02 | 2016-02-02 | 幽门螺杆菌定量和毒力多重基因检测体系及其试剂盒和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610070257.3A CN105506160B (zh) | 2016-02-02 | 2016-02-02 | 幽门螺杆菌定量和毒力多重基因检测体系及其试剂盒和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105506160A CN105506160A (zh) | 2016-04-20 |
CN105506160B true CN105506160B (zh) | 2019-02-26 |
Family
ID=55714450
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610070257.3A Active CN105506160B (zh) | 2016-02-02 | 2016-02-02 | 幽门螺杆菌定量和毒力多重基因检测体系及其试剂盒和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105506160B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105734176B (zh) * | 2016-05-05 | 2020-01-31 | 江西南兴医疗科技有限公司 | 一种联合检测多种性病病原体dna的方法 |
CN108728517B (zh) * | 2018-05-31 | 2023-04-25 | 厦门蓝特生物科技有限公司 | 一种检测幽门螺杆菌空泡毒素vacA的LAMP引物组及其应用 |
CN117187420A (zh) * | 2023-09-12 | 2023-12-08 | 华东医院 | 一种用于口腔样本幽门螺杆菌定量和毒力多重基因检测的体系及产品 |
-
2016
- 2016-02-02 CN CN201610070257.3A patent/CN105506160B/zh active Active
Non-Patent Citations (6)
Title |
---|
不同消化性疾病来源的幽门螺杆菌毒力基因cagA、vacA、oipA、dupA的检测及其意义;徐凯;《中国优秀硕士学位论文全文数据库(医药卫生科技辑)》;20130215(第2期);摘要 |
多重基因分析系统检测幽门螺杆菌的初步研究;周丽芳,等;《检验医学》;20140430;第29卷(第4期);第350-356页 |
幽门螺杆菌生物膜形成与其耐药机制的相关性;胡玢婕,等;《检验医学》;20140831;第29卷(第8期);第865-870页 |
幽门螺杆菌耐药基因的 DNA 序列分析;黄德强;《中国优秀博硕士学位论文全文数据库(硕士)医药卫生科技辑》;20051215(第8期);摘要,第25页 |
芯片检测幽门螺杆菌左氧氟沙星耐药gyrA基因突变的应用;施莉,等;《中华检验医学杂志》;20111231;第34卷(第12期);第1100-1102页 |
贵州省某院幽门螺杆菌致病性的优势基因型特征;李大欢,等;《重庆医学》;20130228;第42卷(第5期);第504-507页 |
Also Published As
Publication number | Publication date |
---|---|
CN105506160A (zh) | 2016-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105441583B (zh) | 幽门螺杆菌多重基因检测体系及其试剂盒和应用 | |
Swidsinski et al. | Association between intraepithelial Escherichia coli and colorectal cancer | |
Sonthayanon et al. | Association of high Orientia tsutsugamushi DNA loads with disease of greater severity in adults with scrub typhus | |
CN104946744B (zh) | 一种多交叉置换扩增核苷酸片段的方法及应用 | |
EP2547782B1 (en) | Methods, kits and compositions for detection of mrsa | |
AU2013353904B2 (en) | Method for detecting Helicobacter pylori DNA in a stool sample | |
Li et al. | Evaluation of multiplex ARMS-PCR for detection of Helicobacter pylori mutations conferring resistance to clarithromycin and levofloxacin | |
Xuan et al. | Detection of clarithromycin-resistant Helicobacter pylori in clinical specimens by molecular methods: A review | |
Schmidt et al. | Distinct cagA EPIYA motifs are associated with ethnic diversity in Malaysia and Singapore | |
CN105506160B (zh) | 幽门螺杆菌定量和毒力多重基因检测体系及其试剂盒和应用 | |
CN105463124B (zh) | 幽门螺杆菌鉴定和毒力多重基因检测体系及其试剂盒和应用 | |
CN104846097A (zh) | 幽门螺旋杆菌分型与耐药突变基因检测试剂盒 | |
Smith et al. | Comparison of PCR with other diagnostic techniques for the detection of H. pylori infection in patients presenting with gastroduodenal symptons in Nigeria | |
Lynn et al. | Genetic typing of the porin protein of Neisseria gonorrhoeae from clinical noncultured samples for strain characterization and identification of mixed gonococcal infections | |
Paton et al. | Methods for detection of STEC in humans: an overview | |
Kanada et al. | Genotyping of the cagA gene of Helicobacter pylori on immunohistochemistry with East Asian CagA‐specific antibody | |
Debruyne et al. | Comparative performance of different PCR assays for the identification of Campylobacter jejuni and Campylobacter coli | |
CN105506161B (zh) | 幽门螺杆菌耐药和定量多重基因检测体系及其试剂盒和应用 | |
CN105441582B (zh) | 幽门螺杆菌定性和定量多重基因检测体系及其试剂盒和应用 | |
Molnar et al. | Significantly elevated Helicobacter pylori density and different genotype distribution in erosions as compared with normal gastric biopsy specimen detected by quantitative real-time PCR | |
Abdollahi et al. | Characterization of helicobacter pylori genotypes from Iranian patients with gastric clinical diseases: predominance of vacA s1a and cagA EPIYA-ABC genotypes | |
CN114438238B (zh) | 检测感染性心内膜炎病原体的引物及数字pcr试剂盒 | |
JP2013504319A (ja) | ヘリコバクター・ピロリ及び/又はクラリスロマイシン抵抗性を検出するためのペプチド核酸プローブ、キット及び方法、及びその使用 | |
CN105368825A (zh) | 幽门螺杆菌抗生素耐药性分析试剂盒及耐药性检测方法 | |
Shan et al. | Multiplex PCR-ASE functionalized microfluidic diagnostic platform for the detection of clarithromycin resistance mutations in Helicobacter pylori |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20180605 Address after: 200040 West Yan'an Road, Jingan District, Shanghai, No. 221 Applicant after: HUADONG Hospital Applicant after: Ningbo Health Gene Technologies Co.,Ltd. Address before: 200040 West Yan'an Road, Jingan District, Shanghai, No. 221 Applicant before: Huadong Hospital |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address |
Address after: 200040 No. 221, Jingan District, Shanghai, West Yan'an Road Patentee after: HUADONG Hospital Country or region after: China Patentee after: Ningbo Haier Shi Gene Technology Co.,Ltd. Address before: 200040 No. 221, Jingan District, Shanghai, West Yan'an Road Patentee before: HUADONG Hospital Country or region before: China Patentee before: Ningbo Health Gene Technologies Co.,Ltd. |